Information:
Fel:
ID
19561
Beskrivning
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00258960
Länk
https://clinicaltrials.gov/show/NCT00258960
Nyckelord
Versioner (1)
- 2017-01-10 2017-01-10 -
Uppladdad den
10 januari 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Breast Cancer NCT00258960
Eligibility Breast Cancer NCT00258960
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT00258960
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Informed Consent
Item
patients must sign an informed consent before of especific procedures of clinical trial.
boolean
C0021430 (UMLS CUI [1])
Breast Carcinoma | erbB-2 Receptor Overexpression
Item
patients with histologically confirmed breast cancer and overexpression of her2neu.
boolean
C0678222 (UMLS CUI [1])
C0069515 (UMLS CUI [2,1])
C1514559 (UMLS CUI [2,2])
C0069515 (UMLS CUI [2,1])
C1514559 (UMLS CUI [2,2])
Age
Item
age> 18 years.
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog equal or < 2.
boolean
C1520224 (UMLS CUI [1])
Chemotherapy Neoplasm Metastasis
Item
patients have not been treated previously with chemotherapy for metastatic disease.
boolean
C0392920 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
Measurable lesion Quantity
Item
patients must have at least one measurable lesion according to recist criteria.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,2])
Organ function Adequate Chemotherapy
Item
patients should have an adequate organ function to tolerate chemotherapy.
boolean
C0678852 (UMLS CUI [1,1])
C0205411 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0205411 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
Hypersensitivity Investigational New Drugs
Item
patients with hypersensitivity reactions to any of the medications of the clinical trial.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0013230 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
patients who are pregnant or lactating are not eligible.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Liver disease
Item
hepatic disease.
boolean
C0023895 (UMLS CUI [1])
Communicable Disease Uncontrolled
Item
not controlled active infection
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,2])
Metastatic malignant neoplasm to brain Symptomatic
Item
symptomatic metastatic brain cancer
boolean
C0220650 (UMLS CUI [1,1])
C0231220 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,2])
Adjuvant therapy Anthracyclines | Doxorubicin Dose Accumulation | Epirubicin Dose Accumulation
Item
previous adyuvant treatment with antrhacyclines with a total accumulated dose > 300 mg/m2 (doxorubicin) or > 600 mg/m2 (epirubicin)
boolean
C0677850 (UMLS CUI [1,1])
C0282564 (UMLS CUI [1,2])
C0013089 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C4055506 (UMLS CUI [2,3])
C0014582 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C4055506 (UMLS CUI [3,3])
C0282564 (UMLS CUI [1,2])
C0013089 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C4055506 (UMLS CUI [2,3])
C0014582 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C4055506 (UMLS CUI [3,3])